BiotechTube

Patritumab + Cetuximab + Cisplatin + Carboplatin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Carcinoma of the Head and Neck

Conditions

Squamous Cell Carcinoma of the Head and Neck

Trial Timeline

Dec 1, 2014 → Jun 1, 2016

NCT ID
NCT02350712

About Patritumab + Cetuximab + Cisplatin + Carboplatin

Patritumab + Cetuximab + Cisplatin + Carboplatin is a phase 1 stage product being developed by Daiichi Sankyo for Squamous Cell Carcinoma of the Head and Neck. The current trial status is completed. This product is registered under clinical trial identifier NCT02350712. Target conditions include Squamous Cell Carcinoma of the Head and Neck.

What happened to similar drugs?

4 of 20 similar drugs in Squamous Cell Carcinoma of the Head and Neck were approved

Approved (4) Terminated (2) Active (14)
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅erlotinib [Tarceva]RocheApproved
✅erlotinib [Tarceva]RocheApproved
✅Platinum-based chemotherapy + Bevacizumab [Avastin]RocheApproved
🔄CT-P51 + EU-approved KeytrudaCelltrionPhase 3
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
🔄Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02350712Phase 1Completed

Competing Products

20 competing products in Squamous Cell Carcinoma of the Head and Neck

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
Cemiplimab + CetuximabEli LillyPhase 2
42
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
BB-401Benitec BiopharmaPhase 2
25
Ramucirumab + PaclitaxelEli LillyPhase 2
35
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
47
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
47
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
39
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
44
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
32
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
24
Drug Combination TherapySun PharmaceuticalPhase 2
42
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
35